Deep B-Cell Depletion: Evolution From Early Proof-of-Concept To Registrational Trials
9:00 am - Wednesday 2nd December 2026
- How different companies in the field are playing to their strengths in choosing which indications to pursue in Phase III
- Using AlloNK as a case study, why Artiva opted to initiate a Phase III trial in rheumatoid arthritis based on the efficacy and safety data generated to date
- Lessons learned during clinical trials and from FDA interactions
